Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00038467
Registration number
NCT00038467
Ethics application status
Date submitted
31/05/2002
Date registered
3/06/2002
Date last updated
7/05/2014
Titles & IDs
Public title
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
Query!
Scientific title
Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen
Query!
Secondary ID [1]
0
0
A5991012
Query!
Secondary ID [2]
0
0
96-OEXE-031
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
IES
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tamoxifen
Treatment: Drugs - Exemestane
Active comparator: B -
Experimental: A -
Treatment: Drugs: Tamoxifen
Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
Treatment: Drugs: Exemestane
Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study
Query!
Assessment method [1]
0
0
DFS defined as time from randomization to earliest documentation of breast cancer relapse or death from any cause. DFS at Month 36 post-randomization was defined as probability of participants alive and disease-free at 36 months after the randomization. Participants withdrawn from the study for any reason in the absence of relapse were censored at the date they were last seen. Relapse was categorized as follows: loco-regional: ipsilateral breast or axillary nodal relapse; distant: distant relapse, including supraclavicular nodes; second primary breast cancer: contralateral breast cancer, excluding ductal carcinoma in situ.
Query!
Timepoint [1]
0
0
Baseline up to Month 36
Query!
Secondary outcome [1]
0
0
Overall Survival (OS) at Month 36 Post-Randomization: Main Study
Query!
Assessment method [1]
0
0
OS was defined as the duration from randomization to death (due to any cause). OS at Month 36 post-randomization was defined as probability of participants' survival at 36 months after the randomization. For participants who were alive, OS was censored at the last available assessment. Probability of OS at Month 36 post-randomization was reported using Kaplan-Meier estimates at Month 36 post-randomization based on 120-month follow-up data.
Query!
Timepoint [1]
0
0
Baseline up to Month 120
Query!
Secondary outcome [2]
0
0
Number of Events of Second Breast Cancer in Contralateral Breast: Main Study
Query!
Assessment method [2]
0
0
Number of events of second primary breast cancer in contralateral breast (excluding ductal carcinoma in situ) were reported.
Query!
Timepoint [2]
0
0
Baseline up to Month 120
Query!
Secondary outcome [3]
0
0
Percent Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) at 6, 12, 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study
Query!
Assessment method [3]
0
0
BMD measurements for Lumbar spine (LS) and Proximal Femur (Total Hip \[TH\]) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [3]
0
0
Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Query!
Secondary outcome [4]
0
0
Percent Change From Baseline in Femoral Neck and Femoral Wards Bone Mineral Density (BMD) at 6, 12 and 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study
Query!
Assessment method [4]
0
0
BMD measurements for femoral neck (FN) and femoral wards (FW) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [4]
0
0
Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Query!
Secondary outcome [5]
0
0
Change From Baseline in Lumbar Spine and Proximal Femur (Total Hip) Bone Mineral Density (BMD) T-scores at 6, 12 and 24 Months On-treatment and 24 Months Post-treatment: Bone Metabolism Sub-study
Query!
Assessment method [5]
0
0
BMD measurements for Lumbar spine (LS) and Proximal Femur (Total Hip \[TH\]) were performed using dual energy X-ray absorptiometry (DXA) for participants who entered the bone-metabolism sub-study. Results were scored as T-score. T-score indicated how many standard deviations higher or lower participant's value was when compared to the young normal reference mean. Using the World Health Organization (WHO) criteria for osteoporosis, a T-score of greater than or equal to (\>=)-1.0 was classified as normal, a T-score of greater than -2.5 to less than -1.0 as osteopenic, and a T-score less than or equal to (\<=)-2.5 as osteoporotic. Here 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [5]
0
0
Baseline, 6, 12, 24 months after randomization (on-treatment), 24 months post-treatment
Query!
Secondary outcome [6]
0
0
Percentage of Bone Specific Alkaline Phosphatase (BAP) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study
Query!
Assessment method [6]
0
0
Bone specific alkaline phosphatase (BAP) serum concentration analyzed using enzyme immuno assay (EIA) at post-baseline time points was expressed as percentage of baseline BAP serum concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [6]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Query!
Secondary outcome [7]
0
0
Percentage of C-Terminal Telopeptide (CTX) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study
Query!
Assessment method [7]
0
0
C-terminal telopeptide (CTX) serum concentration analyzed using competitive enzyme-linked immunosorbent assay (ELISA) at post-baseline time points was expressed as percentage of baseline CTX serum concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [7]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Query!
Secondary outcome [8]
0
0
Percentage of Osteocalcin (OC) and Procollagen T1 C-Peptide (PICP) Serum Concentration Relative to Baseline: Bone Metabolism Sub-study
Query!
Assessment method [8]
0
0
Osteocalcin (OC) serum concentration analyzed using ELISA and procollagen T1 c-peptide (PICP) serum concentration analyzed using sandwich EIA at post-baseline time points was expressed as percentage of baseline OC serum concentration and baseline PICP serum concentration, respectively. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points, for each group respectively.
Query!
Timepoint [8]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Query!
Secondary outcome [9]
0
0
Percentage of Deoxy-pyridinoline (DPD) Urine Concentration Relative to Baseline: Bone Metabolism Sub-study
Query!
Assessment method [9]
0
0
Deoxy-pyridinoline (DPD) urine concentration (adjusted for urinary creatinine) analyzed using competitive EIA at post-baseline time points was expressed as percentage of baseline DPD urine concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [9]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Query!
Secondary outcome [10]
0
0
Percentage of N-telopeptide of Type 1 Collagen (NTX) Urine Concentration Relative to Baseline: Bone Metabolism Sub-study
Query!
Assessment method [10]
0
0
N-telopeptide of Type 1 collagen (NTX) urine concentration (adjusted for urinary creatinine) analyzed using competitive inhibition EIA at post-baseline time points was expressed as percentage of baseline NTX urine concentration. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [10]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30 months after randomization (on-treatment), 36 months after randomization (end of treatment), 12, 24 months post-treatment
Query!
Secondary outcome [11]
0
0
Number of Participants With Fracture: Bone Metabolism Sub-study
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Baseline up to 24 months post-treatment
Query!
Secondary outcome [12]
0
0
Change From Baseline in Treatment Outcome Index (TOI) at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Query!
Assessment method [12]
0
0
The TOI was defined as the sum of 23 items based on following Functional Assessment of Cancer Therapy - Breast version \[FACT-B\] subscales: Physical well-being (7 items), Functional well-being (7 items), Breast cancer subscale (9 items). Each item was scaled from 0='Not at all' to 4='Very much'. Total TOI score ranged from 0 to 92, where higher TOI score indicated better health-related quality of life (QoL). A change of five points in the TOI scores was considered clinically meaningful. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively. Results for 30, 36, 48, 60 months were not reported because data for these time points was only summarized as graphical presentation.
Query!
Timepoint [12]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Query!
Secondary outcome [13]
0
0
Change From Baseline in Functional Assessment of Cancer Therapy - Endocrine Subscale (FACT-ES) Total Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Query!
Assessment method [13]
0
0
The FACT-ES assessed health-related QoL in participants with breast cancer. ES subscale comprised of 18 items (hot flushes,cold sweats,night sweats, vaginal discharge,vaginal irritation,vaginal bleeding,vaginal dryness,discomfort with intercourse,lost interest in sex,gained weight,light headed/dizzy,vomiting,had diarrhea,headaches,felt bloated,breast tenderness,mood swings, felt irritable).Participants indicated how true a statement was for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total FACT-ES score was calculated as sum of all the 18 items and ranged from 0 to 72, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [13]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Query!
Secondary outcome [14]
0
0
Change From Baseline in Total Functional Assessment of Cancer Therapy - General Breast and Endocrine (FACT-GBE) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Query!
Assessment method [14]
0
0
FACT-GBE assessed health-related quality of life (QoL) in participants with breast cancer. It consisted of 56 items,summarized to 7 subscales(subscale 1 to 6 constituted total FACT-B and subscale 7 constituted total ES):physical well-being(7 items), social/family well-being(7 items),relationship with doctor (2 items),emotional well-being(6 items),functional well-being(7 items),breast cancer subscale(9 items),endocrine symptoms(18 items). Participants indicated how true a statement had been for them using 5-point scale from 0(not at all) to 4(very much). For items that were negatively framed,scores were reversed for analysis so that higher scores equated to good QoL. Total FACT-GBE score=sum of all 56 items(range 0 to 224, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [14]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Query!
Secondary outcome [15]
0
0
Change From Baseline in Physical Well-Being (PWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Query!
Assessment method [15]
0
0
The PWB subscale assessed physical well-being related QoL in participants with breast cancer. PWB subscale comprised of 7 items (energy lack, nausea, family needs, pain, side effects, felt ill, forced to stay in bed). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total PWB score was calculated as the sum of all the 7 items and ranged from 0 to 28, where higher score indicated better physical well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [15]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Query!
Secondary outcome [16]
0
0
Change From Baseline in Social/Family Well-Being (SWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Query!
Assessment method [16]
0
0
The SWB subscale assessed social/family well-being related QoL in participants with breast cancer. SWB subscale comprised of 7 items (distant from friends, emotional support, support from friends, family acceptance, family communication, close to main support, sexual satisfaction). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total SWB score was calculated as the sum of all the 7 items and ranged from 0 to 28, where higher score indicated better social/family well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [16]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Query!
Secondary outcome [17]
0
0
Change From Baseline in Relationship With Doctor (RWD) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Substudy
Query!
Assessment method [17]
0
0
The RWD subscale assessed relationship with doctor in participants with breast cancer. RWD subscale comprised of 2 items (confidence in doctors, doctor answered questions). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). Total RWD score was calculated as the sum of the 2 items and ranged from 0 to 8, where higher score indicated better relationship with doctor. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [17]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Query!
Secondary outcome [18]
0
0
Change From Baseline in Emotional Well-Being (EWB) Subscale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Query!
Assessment method [18]
0
0
The EWB subscale assessed emotional well-being related QoL in participants with breast cancer. EWB subscale comprised of 6 items (felt sad, proud of coping, lost hope, felt nervous, worried about dying, worried about condition worsening). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equate to a good QoL. Total EWB score was calculated as the sum of the 6 items and ranged from 0 to 24, where higher score indicated better emotional well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [18]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Query!
Secondary outcome [19]
0
0
Change From Baseline in Functional Well-Being (FWB) Sub-scale Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Query!
Assessment method [19]
0
0
The FWB subscale assessed functional well-being related QoL in participants with breast cancer. FWB subscale comprised of 7 items (able to work, work fulfilled, able to enjoy life, acceptance of illness, sleeping well, enjoyed normal fun activities, contented with QoL). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). Total FWB score was calculated as the sum of the 7 items and ranged from 0 to 28, where higher score indicated better functional well-being related QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [19]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Query!
Secondary outcome [20]
0
0
Change From Baseline in Breast Cancer Subscale (BCS) Score at 3, 6, 9, 12, 18, 24, 30, 36, 48 and 60 Months: QoL Sub-study
Query!
Assessment method [20]
0
0
The BCS subscale assessed health related QoL in participants with breast cancer. BCS subscale comprised of 9 items (short of breath, self-conscious dress, tender/swollen arms, sexually attractive, bothered by hair loss, worried about familial risk, worried about family stress, bothered by weight change, able to feel like a woman). Participants indicated how true a statement had been for them using a 5-point scale from 0 (not at all) to 4 (very much). For items that were negatively framed, the scores were reversed for the analysis so that higher scores equated to a good QoL. Total BCS score was calculated as the sum of the 9 items and ranged from 0 to 36, where higher score indicated better QoL. 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [20]
0
0
Baseline, 3, 6, 9, 12, 18, 24, 30, 36, 48, 60 months after randomization
Query!
Secondary outcome [21]
0
0
Number of Participants With Severe Endocrine Symptoms: QoL Sub-study
Query!
Assessment method [21]
0
0
Participants indicated prevalence of an endocrine subscale items using a 5-point scale, where 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). Endocrine items were grouped in five categories vasomotor (hot flushes, cold sweats, night sweats, sleeping difficulties), neuropsychological (lack of energy, nervous feeling, lightheaded/dizzy, headaches, mood swings, feeling irritable), gastrointestinal symptoms (nausea, gained weight, vomiting, diarrhea, bloated feeling), gynecological symptoms (vaginal discharge, vaginal irritation, vaginal bleeding, vaginal dryness, discomfort with intercourse, lost interest in sex, breast tenderness) and other symptoms (pain, feeling ill, side effects). Number of participants who reported severe endocrine symptoms (defined as response categories "quite a bit" and "very much") were presented.
Query!
Timepoint [21]
0
0
Baseline up to 24 months after randomization
Query!
Secondary outcome [22]
0
0
Percentage of Participants With Endometrial Thickness Greater Than or Equal to (>=) 5 Millimeter (mm): Endometrial Sub-study
Query!
Assessment method [22]
0
0
Endometrial thickness was assessed using transvaginal ultrasound examination. 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [22]
0
0
6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Query!
Secondary outcome [23]
0
0
Endometrial Thickness: Endometrial Sub-study
Query!
Assessment method [23]
0
0
Endometrial thickness was assessed using transvaginal ultrasound examination. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [23]
0
0
Baseline, 6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Query!
Secondary outcome [24]
0
0
Uterine and Overall Ovary Volume: Endometrial Sub-study
Query!
Assessment method [24]
0
0
Uterine volume (UV) and ovarian volume was estimated using ultrasonography. Uterine volume = (longitudinal diameter \* transverse diameter \* anteroposterior diameter of uterus)/(2\*1000). Ovary volume = \[(longitudinal diameter \* transverse diameter \* anteroposterior diameter of ovary) \* 3.14\]/(6\*1000). Overall ovary volume (OV) is calculated as the sum of the right and left ovary volume. 'N' (number of participants analyzed) signifies those participants who were evaluable for this outcome and 'n' signifies those participants who were evaluable for this measure at given time points for each group, respectively.
Query!
Timepoint [24]
0
0
6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Query!
Secondary outcome [25]
0
0
Number of Participants With Polyps, Fibroids and Ovarian Cysts: Endometrial Sub-study
Query!
Assessment method [25]
0
0
Number of participants with presence of polyps (POL) and fibroids (FIB) at post-baseline time points compared to the baseline (BL) status of 'yes', 'no' or 'missing' (that is, participants reporting POL/FIB at post-baseline time points who had yes, no or missing POL/FIB status at baseline, respectively) were presented. Result for number of participants with ovarian cysts was not analyzed at post-baseline time points as very few participants reported ovarian cysts at baseline.
Query!
Timepoint [25]
0
0
6, 12, 24, 36 months after randomization, 6, 12, 24 months post-treatment
Query!
Secondary outcome [26]
0
0
Percentage of Participants With at Least 1 Gynecological Symptoms: Endometrial Sub-study
Query!
Assessment method [26]
0
0
Gynecological symptoms included bleeding/spotting, pelvic pain, leucorrhoea and vaginal itching.
Query!
Timepoint [26]
0
0
Baseline up to 24 months post-treatment
Query!
Secondary outcome [27]
0
0
Number of Participants With Histological Findings: Endometrial Sub-study
Query!
Assessment method [27]
0
0
Query!
Timepoint [27]
0
0
Baseline up to 24 months post-treatment
Query!
Eligibility
Key inclusion criteria
* postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease
Query!
Minimum age
30
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* unresectable breast cancer
* ER negative primary tumor
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/1998
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
4740
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Pfizer Investigational Site - Camperdown
Query!
Recruitment hospital [2]
0
0
Pfizer Investigational Site - Dubbo
Query!
Recruitment hospital [3]
0
0
Pfizer Investigational Site - Liverpool
Query!
Recruitment hospital [4]
0
0
Pfizer Investigational Site - Waratah
Query!
Recruitment hospital [5]
0
0
Pfizer Investigational Site - Adelaide
Query!
Recruitment hospital [6]
0
0
Pfizer Investigational Site - Bendigo
Query!
Recruitment hospital [7]
0
0
Pfizer Investigational Site - Box Hill
Query!
Recruitment hospital [8]
0
0
Pfizer Investigational Site - Ringwood East
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2830 - Dubbo
Query!
Recruitment postcode(s) [3]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [4]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [5]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [6]
0
0
3552 - Bendigo
Query!
Recruitment postcode(s) [7]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [8]
0
0
3135 - Ringwood East
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Indiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Oregon
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Texas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Washington
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
Buenos Aires
Query!
Country [13]
0
0
Argentina
Query!
State/province [13]
0
0
Capital Federal
Query!
Country [14]
0
0
Argentina
Query!
State/province [14]
0
0
Pcia. de Santa Fe
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Santa Fe
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Cordoba
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Antwerpen
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Arlon
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Baudour
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Brasschaat
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Bruxelles
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Charleroi
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Edegem
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Genk
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Haine St. Paul
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Hasselt
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Kraainem
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
La Louviere
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Leuven
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Liege
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Merksem
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Namur
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Verviers
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Wilrijk
Query!
Country [35]
0
0
Bosnia and Herzegovina
Query!
State/province [35]
0
0
Sarajevo
Query!
Country [36]
0
0
Bulgaria
Query!
State/province [36]
0
0
Plovdiv
Query!
Country [37]
0
0
Bulgaria
Query!
State/province [37]
0
0
Sofia
Query!
Country [38]
0
0
Bulgaria
Query!
State/province [38]
0
0
Stara Zagora
Query!
Country [39]
0
0
Croatia
Query!
State/province [39]
0
0
Osijek
Query!
Country [40]
0
0
Croatia
Query!
State/province [40]
0
0
Split
Query!
Country [41]
0
0
Croatia
Query!
State/province [41]
0
0
Zagreb
Query!
Country [42]
0
0
Czech Republic
Query!
State/province [42]
0
0
Brno
Query!
Country [43]
0
0
Czech Republic
Query!
State/province [43]
0
0
Ceske Budejovice
Query!
Country [44]
0
0
Czech Republic
Query!
State/province [44]
0
0
Prague 2
Query!
Country [45]
0
0
Denmark
Query!
State/province [45]
0
0
Aarhus C
Query!
Country [46]
0
0
Denmark
Query!
State/province [46]
0
0
Esbjerg
Query!
Country [47]
0
0
Denmark
Query!
State/province [47]
0
0
Herlev
Query!
Country [48]
0
0
Denmark
Query!
State/province [48]
0
0
Herning
Query!
Country [49]
0
0
Denmark
Query!
State/province [49]
0
0
Hilleroed
Query!
Country [50]
0
0
Denmark
Query!
State/province [50]
0
0
Koebenhavn OE
Query!
Country [51]
0
0
Denmark
Query!
State/province [51]
0
0
Naestved
Query!
Country [52]
0
0
Denmark
Query!
State/province [52]
0
0
Roskilde
Query!
Country [53]
0
0
Denmark
Query!
State/province [53]
0
0
Vejle
Query!
Country [54]
0
0
Denmark
Query!
State/province [54]
0
0
Viborg
Query!
Country [55]
0
0
Egypt
Query!
State/province [55]
0
0
Cairo
Query!
Country [56]
0
0
Estonia
Query!
State/province [56]
0
0
Tartu
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Angers
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Annecy Cedex
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Avignon Cedex 2
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Bordeaux
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Brest
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Caen Cedex 05
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Caen
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Clermont Ferrand
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Evreux
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Lagny Sur Marne
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Le Havre
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Le Mans
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Lille
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Lyon
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Marseille
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Meaux
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Montbeliard
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Mulhouse
Query!
Country [75]
0
0
France
Query!
State/province [75]
0
0
Nice
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Paris
Query!
Country [77]
0
0
France
Query!
State/province [77]
0
0
Perpignan
Query!
Country [78]
0
0
France
Query!
State/province [78]
0
0
Rennes
Query!
Country [79]
0
0
France
Query!
State/province [79]
0
0
Rouen
Query!
Country [80]
0
0
France
Query!
State/province [80]
0
0
Saint-Herblain
Query!
Country [81]
0
0
France
Query!
State/province [81]
0
0
St Cloud
Query!
Country [82]
0
0
France
Query!
State/province [82]
0
0
Strasbourg
Query!
Country [83]
0
0
France
Query!
State/province [83]
0
0
Toulouse
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Berlin
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Chemnitz
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Erlangen
Query!
Country [87]
0
0
Germany
Query!
State/province [87]
0
0
Freiburg
Query!
Country [88]
0
0
Germany
Query!
State/province [88]
0
0
Gera
Query!
Country [89]
0
0
Germany
Query!
State/province [89]
0
0
Greiz
Query!
Country [90]
0
0
Germany
Query!
State/province [90]
0
0
Halle
Query!
Country [91]
0
0
Germany
Query!
State/province [91]
0
0
Hamburg
Query!
Country [92]
0
0
Germany
Query!
State/province [92]
0
0
Hildburghausen
Query!
Country [93]
0
0
Germany
Query!
State/province [93]
0
0
Leipzig
Query!
Country [94]
0
0
Germany
Query!
State/province [94]
0
0
Luebeck
Query!
Country [95]
0
0
Germany
Query!
State/province [95]
0
0
Muenchen
Query!
Country [96]
0
0
Germany
Query!
State/province [96]
0
0
Riesa
Query!
Country [97]
0
0
Germany
Query!
State/province [97]
0
0
Rodewisch
Query!
Country [98]
0
0
Germany
Query!
State/province [98]
0
0
Saarbruecken
Query!
Country [99]
0
0
Germany
Query!
State/province [99]
0
0
Suhl
Query!
Country [100]
0
0
Germany
Query!
State/province [100]
0
0
Weiden
Query!
Country [101]
0
0
Greece
Query!
State/province [101]
0
0
Attiki
Query!
Country [102]
0
0
Greece
Query!
State/province [102]
0
0
Crete
Query!
Country [103]
0
0
Hong Kong
Query!
State/province [103]
0
0
New Territories
Query!
Country [104]
0
0
Hungary
Query!
State/province [104]
0
0
Budapest
Query!
Country [105]
0
0
Ireland
Query!
State/province [105]
0
0
Cork, Ireland
Query!
Country [106]
0
0
Ireland
Query!
State/province [106]
0
0
Cork
Query!
Country [107]
0
0
Ireland
Query!
State/province [107]
0
0
Dublin 9
Query!
Country [108]
0
0
Ireland
Query!
State/province [108]
0
0
Dublin
Query!
Country [109]
0
0
Ireland
Query!
State/province [109]
0
0
Galway
Query!
Country [110]
0
0
Israel
Query!
State/province [110]
0
0
Haifa
Query!
Country [111]
0
0
Israel
Query!
State/province [111]
0
0
Jerusalem
Query!
Country [112]
0
0
Israel
Query!
State/province [112]
0
0
Kfar Saba
Query!
Country [113]
0
0
Israel
Query!
State/province [113]
0
0
Petah Tikva
Query!
Country [114]
0
0
Israel
Query!
State/province [114]
0
0
Rehovot
Query!
Country [115]
0
0
Italy
Query!
State/province [115]
0
0
Modena
Query!
Country [116]
0
0
Italy
Query!
State/province [116]
0
0
Alba (CN)
Query!
Country [117]
0
0
Italy
Query!
State/province [117]
0
0
Aviano (PN)
Query!
Country [118]
0
0
Italy
Query!
State/province [118]
0
0
Bergamo
Query!
Country [119]
0
0
Italy
Query!
State/province [119]
0
0
Biella
Query!
Country [120]
0
0
Italy
Query!
State/province [120]
0
0
Cagliari
Query!
Country [121]
0
0
Italy
Query!
State/province [121]
0
0
Casale Monferrato, AL
Query!
Country [122]
0
0
Italy
Query!
State/province [122]
0
0
Correggio
Query!
Country [123]
0
0
Italy
Query!
State/province [123]
0
0
Cremona
Query!
Country [124]
0
0
Italy
Query!
State/province [124]
0
0
Cuneo
Query!
Country [125]
0
0
Italy
Query!
State/province [125]
0
0
Fermo FM
Query!
Country [126]
0
0
Italy
Query!
State/province [126]
0
0
Firenze
Query!
Country [127]
0
0
Italy
Query!
State/province [127]
0
0
Genova
Query!
Country [128]
0
0
Italy
Query!
State/province [128]
0
0
Lecco
Query!
Country [129]
0
0
Italy
Query!
State/province [129]
0
0
Lodi
Query!
Country [130]
0
0
Italy
Query!
State/province [130]
0
0
Mantova
Query!
Country [131]
0
0
Italy
Query!
State/province [131]
0
0
Milano
Query!
Country [132]
0
0
Italy
Query!
State/province [132]
0
0
Monserrato (CA)
Query!
Country [133]
0
0
Italy
Query!
State/province [133]
0
0
Monza
Query!
Country [134]
0
0
Italy
Query!
State/province [134]
0
0
Napoli
Query!
Country [135]
0
0
Italy
Query!
State/province [135]
0
0
Palermo
Query!
Country [136]
0
0
Italy
Query!
State/province [136]
0
0
Parma
Query!
Country [137]
0
0
Italy
Query!
State/province [137]
0
0
Perugia
Query!
Country [138]
0
0
Italy
Query!
State/province [138]
0
0
Piacenza
Query!
Country [139]
0
0
Italy
Query!
State/province [139]
0
0
Pietra Ligure (SV)
Query!
Country [140]
0
0
Italy
Query!
State/province [140]
0
0
Pisa
Query!
Country [141]
0
0
Italy
Query!
State/province [141]
0
0
Reggio Emilia
Query!
Country [142]
0
0
Italy
Query!
State/province [142]
0
0
Roma
Query!
Country [143]
0
0
Italy
Query!
State/province [143]
0
0
Sassari
Query!
Country [144]
0
0
Italy
Query!
State/province [144]
0
0
Terni
Query!
Country [145]
0
0
Italy
Query!
State/province [145]
0
0
Thiene (VI)
Query!
Country [146]
0
0
Italy
Query!
State/province [146]
0
0
Torino
Query!
Country [147]
0
0
Italy
Query!
State/province [147]
0
0
Tortona
Query!
Country [148]
0
0
Italy
Query!
State/province [148]
0
0
Trescore Balneario BG
Query!
Country [149]
0
0
Italy
Query!
State/province [149]
0
0
Treviglio (BG)
Query!
Country [150]
0
0
Italy
Query!
State/province [150]
0
0
Varese
Query!
Country [151]
0
0
Luxembourg
Query!
State/province [151]
0
0
Luxembourg
Query!
Country [152]
0
0
Malta
Query!
State/province [152]
0
0
Floriana
Query!
Country [153]
0
0
Netherlands
Query!
State/province [153]
0
0
Amersfoort
Query!
Country [154]
0
0
Netherlands
Query!
State/province [154]
0
0
Amsterdam
Query!
Country [155]
0
0
Netherlands
Query!
State/province [155]
0
0
Apeldoorn
Query!
Country [156]
0
0
Netherlands
Query!
State/province [156]
0
0
Blaricum
Query!
Country [157]
0
0
Netherlands
Query!
State/province [157]
0
0
Breda
Query!
Country [158]
0
0
Netherlands
Query!
State/province [158]
0
0
Delft
Query!
Country [159]
0
0
Netherlands
Query!
State/province [159]
0
0
Den Haag
Query!
Country [160]
0
0
Netherlands
Query!
State/province [160]
0
0
Eindhoven
Query!
Country [161]
0
0
Netherlands
Query!
State/province [161]
0
0
Enschede
Query!
Country [162]
0
0
Netherlands
Query!
State/province [162]
0
0
Groningen
Query!
Country [163]
0
0
Netherlands
Query!
State/province [163]
0
0
Hengelo
Query!
Country [164]
0
0
Netherlands
Query!
State/province [164]
0
0
Leeuwarden
Query!
Country [165]
0
0
Netherlands
Query!
State/province [165]
0
0
Leiden
Query!
Country [166]
0
0
Netherlands
Query!
State/province [166]
0
0
Leidschendam
Query!
Country [167]
0
0
Netherlands
Query!
State/province [167]
0
0
Podybus 90153
Query!
Country [168]
0
0
Netherlands
Query!
State/province [168]
0
0
Roermond
Query!
Country [169]
0
0
Netherlands
Query!
State/province [169]
0
0
Sittard
Query!
Country [170]
0
0
Netherlands
Query!
State/province [170]
0
0
Utrecht
Query!
Country [171]
0
0
Netherlands
Query!
State/province [171]
0
0
Veldhoven
Query!
Country [172]
0
0
Netherlands
Query!
State/province [172]
0
0
Zaandam
Query!
Country [173]
0
0
New Zealand
Query!
State/province [173]
0
0
Waikato
Query!
Country [174]
0
0
New Zealand
Query!
State/province [174]
0
0
Auckland
Query!
Country [175]
0
0
Norway
Query!
State/province [175]
0
0
Bergen
Query!
Country [176]
0
0
Norway
Query!
State/province [176]
0
0
Bodo
Query!
Country [177]
0
0
Norway
Query!
State/province [177]
0
0
Fredrikstad
Query!
Country [178]
0
0
Norway
Query!
State/province [178]
0
0
Haugesund
Query!
Country [179]
0
0
Norway
Query!
State/province [179]
0
0
Levanger
Query!
Country [180]
0
0
Norway
Query!
State/province [180]
0
0
Mo i Rana
Query!
Country [181]
0
0
Norway
Query!
State/province [181]
0
0
Molde
Query!
Country [182]
0
0
Norway
Query!
State/province [182]
0
0
Notodden
Query!
Country [183]
0
0
Norway
Query!
State/province [183]
0
0
Oslo
Query!
Country [184]
0
0
Norway
Query!
State/province [184]
0
0
Rissa
Query!
Country [185]
0
0
Norway
Query!
State/province [185]
0
0
Rjukan
Query!
Country [186]
0
0
Norway
Query!
State/province [186]
0
0
Sandefjord
Query!
Country [187]
0
0
Norway
Query!
State/province [187]
0
0
Tonsberg
Query!
Country [188]
0
0
Norway
Query!
State/province [188]
0
0
Tromso
Query!
Country [189]
0
0
Norway
Query!
State/province [189]
0
0
Tromsø
Query!
Country [190]
0
0
Peru
Query!
State/province [190]
0
0
Lima
Query!
Country [191]
0
0
Poland
Query!
State/province [191]
0
0
Gdansk
Query!
Country [192]
0
0
Poland
Query!
State/province [192]
0
0
Gliwice
Query!
Country [193]
0
0
Poland
Query!
State/province [193]
0
0
Krakow
Query!
Country [194]
0
0
Poland
Query!
State/province [194]
0
0
Lodz
Query!
Country [195]
0
0
Poland
Query!
State/province [195]
0
0
Opole
Query!
Country [196]
0
0
Poland
Query!
State/province [196]
0
0
Poznan
Query!
Country [197]
0
0
Poland
Query!
State/province [197]
0
0
Sopot
Query!
Country [198]
0
0
Poland
Query!
State/province [198]
0
0
Warszawa
Query!
Country [199]
0
0
Portugal
Query!
State/province [199]
0
0
Coimbra
Query!
Country [200]
0
0
Portugal
Query!
State/province [200]
0
0
Evora
Query!
Country [201]
0
0
Romania
Query!
State/province [201]
0
0
Bucuresti
Query!
Country [202]
0
0
Romania
Query!
State/province [202]
0
0
Cluj Napoca
Query!
Country [203]
0
0
Romania
Query!
State/province [203]
0
0
Timisoara
Query!
Country [204]
0
0
Russian Federation
Query!
State/province [204]
0
0
St. Petersburg
Query!
Country [205]
0
0
Serbia
Query!
State/province [205]
0
0
Belgrade
Query!
Country [206]
0
0
Serbia
Query!
State/province [206]
0
0
Sremska Kamenica
Query!
Country [207]
0
0
Slovakia
Query!
State/province [207]
0
0
Banska Bystrica
Query!
Country [208]
0
0
Slovakia
Query!
State/province [208]
0
0
Bratislava
Query!
Country [209]
0
0
Slovakia
Query!
State/province [209]
0
0
Kosice
Query!
Country [210]
0
0
Slovenia
Query!
State/province [210]
0
0
Ljubljana
Query!
Country [211]
0
0
South Africa
Query!
State/province [211]
0
0
Gauteng
Query!
Country [212]
0
0
South Africa
Query!
State/province [212]
0
0
Observatory
Query!
Country [213]
0
0
Spain
Query!
State/province [213]
0
0
Alicante
Query!
Country [214]
0
0
Spain
Query!
State/province [214]
0
0
Barcelona
Query!
Country [215]
0
0
Spain
Query!
State/province [215]
0
0
Guipuzcoa
Query!
Country [216]
0
0
Spain
Query!
State/province [216]
0
0
Huesca
Query!
Country [217]
0
0
Spain
Query!
State/province [217]
0
0
Tarragona
Query!
Country [218]
0
0
Spain
Query!
State/province [218]
0
0
Albacete
Query!
Country [219]
0
0
Spain
Query!
State/province [219]
0
0
Badajoz
Query!
Country [220]
0
0
Spain
Query!
State/province [220]
0
0
Cordoba
Query!
Country [221]
0
0
Spain
Query!
State/province [221]
0
0
Guadalajara
Query!
Country [222]
0
0
Spain
Query!
State/province [222]
0
0
Lleida
Query!
Country [223]
0
0
Spain
Query!
State/province [223]
0
0
Madrid
Query!
Country [224]
0
0
Spain
Query!
State/province [224]
0
0
Valencia
Query!
Country [225]
0
0
Spain
Query!
State/province [225]
0
0
Zaragoza
Query!
Country [226]
0
0
Sweden
Query!
State/province [226]
0
0
Boras
Query!
Country [227]
0
0
Sweden
Query!
State/province [227]
0
0
Borås
Query!
Country [228]
0
0
Sweden
Query!
State/province [228]
0
0
Goteborg
Query!
Country [229]
0
0
Sweden
Query!
State/province [229]
0
0
Halmstad
Query!
Country [230]
0
0
Sweden
Query!
State/province [230]
0
0
Helsingborg
Query!
Country [231]
0
0
Sweden
Query!
State/province [231]
0
0
Kristianstad
Query!
Country [232]
0
0
Sweden
Query!
State/province [232]
0
0
Linkoping
Query!
Country [233]
0
0
Sweden
Query!
State/province [233]
0
0
Lund
Query!
Country [234]
0
0
Sweden
Query!
State/province [234]
0
0
Malmo
Query!
Country [235]
0
0
Sweden
Query!
State/province [235]
0
0
Motala
Query!
Country [236]
0
0
Sweden
Query!
State/province [236]
0
0
Norrkoping
Query!
Country [237]
0
0
Sweden
Query!
State/province [237]
0
0
Nässjö
Query!
Country [238]
0
0
Sweden
Query!
State/province [238]
0
0
Varnamo
Query!
Country [239]
0
0
Sweden
Query!
State/province [239]
0
0
Vasteras
Query!
Country [240]
0
0
Sweden
Query!
State/province [240]
0
0
Vastervik
Query!
Country [241]
0
0
Sweden
Query!
State/province [241]
0
0
Vaxjo
Query!
Country [242]
0
0
Switzerland
Query!
State/province [242]
0
0
Basel
Query!
Country [243]
0
0
Switzerland
Query!
State/province [243]
0
0
Bellinzona
Query!
Country [244]
0
0
Switzerland
Query!
State/province [244]
0
0
Bern
Query!
Country [245]
0
0
Switzerland
Query!
State/province [245]
0
0
Genève
Query!
Country [246]
0
0
United Kingdom
Query!
State/province [246]
0
0
Cambs
Query!
Country [247]
0
0
United Kingdom
Query!
State/province [247]
0
0
Dorset
Query!
Country [248]
0
0
United Kingdom
Query!
State/province [248]
0
0
East Yorkshire
Query!
Country [249]
0
0
United Kingdom
Query!
State/province [249]
0
0
Essex
Query!
Country [250]
0
0
United Kingdom
Query!
State/province [250]
0
0
Gwent
Query!
Country [251]
0
0
United Kingdom
Query!
State/province [251]
0
0
Gwynedd
Query!
Country [252]
0
0
United Kingdom
Query!
State/province [252]
0
0
Halifax
Query!
Country [253]
0
0
United Kingdom
Query!
State/province [253]
0
0
Hants
Query!
Country [254]
0
0
United Kingdom
Query!
State/province [254]
0
0
Middlesex
Query!
Country [255]
0
0
United Kingdom
Query!
State/province [255]
0
0
N. Ireland
Query!
Country [256]
0
0
United Kingdom
Query!
State/province [256]
0
0
N. Yorkshire
Query!
Country [257]
0
0
United Kingdom
Query!
State/province [257]
0
0
Somerset
Query!
Country [258]
0
0
United Kingdom
Query!
State/province [258]
0
0
South Wales
Query!
Country [259]
0
0
United Kingdom
Query!
State/province [259]
0
0
Yorkshire
Query!
Country [260]
0
0
United Kingdom
Query!
State/province [260]
0
0
Belfast
Query!
Country [261]
0
0
United Kingdom
Query!
State/province [261]
0
0
Bradford
Query!
Country [262]
0
0
United Kingdom
Query!
State/province [262]
0
0
Bristol
Query!
Country [263]
0
0
United Kingdom
Query!
State/province [263]
0
0
Cardiff
Query!
Country [264]
0
0
United Kingdom
Query!
State/province [264]
0
0
Coventry
Query!
Country [265]
0
0
United Kingdom
Query!
State/province [265]
0
0
East Kilbride
Query!
Country [266]
0
0
United Kingdom
Query!
State/province [266]
0
0
Huddersfield
Query!
Country [267]
0
0
United Kingdom
Query!
State/province [267]
0
0
Leeds
Query!
Country [268]
0
0
United Kingdom
Query!
State/province [268]
0
0
Lincoln
Query!
Country [269]
0
0
United Kingdom
Query!
State/province [269]
0
0
London
Query!
Country [270]
0
0
United Kingdom
Query!
State/province [270]
0
0
Luton
Query!
Country [271]
0
0
United Kingdom
Query!
State/province [271]
0
0
Manchester
Query!
Country [272]
0
0
United Kingdom
Query!
State/province [272]
0
0
Sheffield
Query!
Country [273]
0
0
United Kingdom
Query!
State/province [273]
0
0
Shrewsbury
Query!
Country [274]
0
0
United Kingdom
Query!
State/province [274]
0
0
Southampton
Query!
Country [275]
0
0
United Kingdom
Query!
State/province [275]
0
0
Steeton
Query!
Country [276]
0
0
United Kingdom
Query!
State/province [276]
0
0
Stoke on Trent
Query!
Country [277]
0
0
United Kingdom
Query!
State/province [277]
0
0
Telford
Query!
Country [278]
0
0
United Kingdom
Query!
State/province [278]
0
0
Wythenshawe, Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
International Collaborative Cancer Group
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00038467
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00038467
Download to PDF